Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493159 | 0.84 | SIGMAR1 (0.47) | APPDRD2SIGMAR1HTR2AHTR2C | |
| SCHEMBL7127231 | 0.79 | SIGMAR1 (0.46) | APPDRD2SIGMAR1HTR2AHTR2C | |
| SCHEMBL6493047 | 0.77 | CA1 (0.44) | APPDRD2SIGMAR1CCR5 | |
| SCHEMBL6503951 | 0.76 | DRD2 (0.40) | DRD2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL8203575 | 0.75 | DRD2 (0.45) | DRD2DRD4DRD3SIGMAR1HTR2A | |
| SCHEMBL6499626 | 0.74 | DRD2 (0.44) | APPDRD2SIGMAR1CCR5 | |
| SCHEMBL7949210 | 0.74 | APP (0.44) | APPDRD2SIGMAR1HTR2AHTR2C | |
| SCHEMBL8191001 | 0.74 | ADRA1D (0.51) | DRD2SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL6500886 | 0.72 | MTNR1B (0.45) | APPDRD2SIGMAR1OPRM1CCR5 | |
| SCHEMBL8200589 | 0.72 | MTNR1B (0.45) | APPDRD2SIGMAR1OPRM1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | S ATWAL KARNAIL (US) | 2003-06-19 | — | — | US | claimed |
| US-6664250-B2 | Cardiovascular disorders | BRISTOL-MYERS SQUIBB CO. | 2003-12-16 | — | — | US | disclosed |
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | S ATWAL KARNAIL (US) | 2003-06-19 | — | — | US | disclosed |
| US-6262068-B1 | ISOQUINOLONES | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | NPR3, SCN3A, NRDC | APP 3322/4885DRD2 1143/4885DRD4 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.